Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santhera Completes Acquisition Of Juvantia
Santhera has reported that it has exercised its option to acquire Oy Juvantia Pharma, the owner of JP-1730/fipamezole. Reportedly, the company will issue up to 105,973 previously reserved
Santhera has reported that it has exercised its option to acquire Oy Juvantia Pharma, the owner of JP-1730/fipamezole. Reportedly, the company will issue up to 105,973 previously reserved
China-Biotics has reported an increase in net sales during the first quarter of 2010 fiscal year by 35.5% to $15.4m, from $11.4m a year ago. Gross profit for
Eli Lilly has reported that the US District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment. Reportedly, the
AlphaRx has completed the lyophilization process for Zysolin, allowing the company to proceed to clinical batch material manufacturing for human trials. The company said that the process has
Aurobindo Pharma (Aurobindo) has reported that it will acquire Trident Life Sciences (TLSL) for an undisclosed amount. The company said that the board has approved the acquisition of
SonoSite has acquired CardioDynamics. Under the terms of the agreement, CardioDynamics will become a wholly-owned subsidiary of SonoSite and CardioDynamics’ shareholders will receive $1.35 per share in cash.
NeuroSearch has signed a drug discovery and drug development agreement with Janssen Pharmaceutica (Janssen). As per the agreement, NeuroSearch and Janssen will collaborate to discover, develop and commercialise
A new consortium has been formed to boost drug development for the treatment of two diseases, African sleeping sickness and leishmaniasis. Reportedly, the new consortium will target parasite-specific
Researchers from the University of Pittsburgh have reported two nanoscale devices (recently in two separate journals) harness the potential of carbon nanomaterials to enhance technologies for drug or
AEterna Zentaris has reported phase 3 results for its North American efficacy trial – Z-033 and the safety trial – Z-041 in benign prostatic hyperplasia (BPH), with its